New Risk • Jun 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.57b market cap, or US$16.6m). Reported Earnings • May 30
Full year 2026 earnings released: EPS: ₹10.27 (vs ₹10.03 in FY 2025) Full year 2026 results: EPS: ₹10.27 (up from ₹10.03 in FY 2025). Revenue: ₹2.52b (up 34% from FY 2025). Net income: ₹117.8m (up 2.2% from FY 2025). Profit margin: 4.7% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 21
Parnax Lab Limited to Report Q4, 2026 Results on May 28, 2026 Parnax Lab Limited announced that they will report Q4, 2026 results on May 28, 2026 Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹160, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹137, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹2.37 (vs ₹1.06 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.37 (up from ₹1.06 in 3Q 2025). Revenue: ₹639.1m (up 59% from 3Q 2025). Net income: ₹27.1m (up 124% from 3Q 2025). Profit margin: 4.2% (up from 3.0% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 05
Parnax Lab Limited to Report Q3, 2026 Results on Feb 13, 2026 Parnax Lab Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (65% net debt to equity). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹1.42b market cap, or US$15.5m). Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹3.15 (vs ₹2.97 in 2Q 2025) Second quarter 2026 results: EPS: ₹3.15 (up from ₹2.97 in 2Q 2025). Revenue: ₹632.3m (up 31% from 2Q 2025). Net income: ₹36.3m (up 6.5% from 2Q 2025). Profit margin: 5.7% (down from 7.0% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 03
Parnax Lab Limited to Report Q2, 2026 Results on Nov 14, 2025 Parnax Lab Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Aug 14
Parnax Lab Limited, Annual General Meeting, Sep 29, 2025 Parnax Lab Limited, Annual General Meeting, Sep 29, 2025. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹2.85 (vs ₹3.47 in 1Q 2025) First quarter 2026 results: EPS: ₹2.85 (down from ₹3.47 in 1Q 2025). Revenue: ₹535.6m (up 6.9% from 1Q 2025). Net income: ₹32.7m (down 18% from 1Q 2025). Profit margin: 6.1% (down from 7.9% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 8% per year. Announcement • Aug 06
Parnax Lab Limited to Report Q1, 2026 Results on Aug 13, 2025 Parnax Lab Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹126, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹111, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.7% over the past three years. Reported Earnings • May 28
Full year 2025 earnings released: EPS: ₹10.05 (vs ₹8.37 in FY 2024) Full year 2025 results: EPS: ₹10.05 (up from ₹8.37 in FY 2024). Revenue: ₹1.89b (flat on FY 2024). Net income: ₹115.2m (up 20% from FY 2024). Profit margin: 6.1% (up from 5.1% in FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • May 20
Parnax Lab Limited to Report Q4, 2025 Results on May 27, 2025 Parnax Lab Limited announced that they will report Q4, 2025 results on May 27, 2025 Valuation Update With 7 Day Price Move • Mar 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 21% over the past three years. Announcement • Mar 21
Parnax Lab Limited Announces Executive Changes Parnax Lab Limited at its meeting had inter-alia considered and approved the following: Special Resolution: Appointment of Mr. Vijay Kumar Ayare (DIN: 06383445) as a Non- Executive & Independent Director of the Company, on the Board of the Company, by the Shareholders to hold office for a term up to 5 (five) consecutive years from the date of appointment i. e. 10 February, 2025 to 09 February, 2030, not liable to retire by rotation. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Mihir P. Shah, as a Managing Director and CEO, from Director and CEO of the Company. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Binoy B. Shah, as an Executive Director and CFO, from Managing Director and CFO of the Company. Mr. Vijay Kumar Ayare is having 50+ years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Wanbury Group. Mr. Vijay Kumar Ayare is committed to harnessing the growth potential of Wanbury Group by catering to the demands of the industry with professionalism and a differentiated service offering. At the core of Wanbury Group, Mr. Vijay Kumar Ayare is one of the qualified and passionate in management team, who has behind him skill and experience. It is as a result of his diligence and perseverance that Wanbury's prowess in pharmaceutical manufacturing has seen exponential growth and achievement. He is Diligent in Strategy and planning, Deal Evaluation and Structuring. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years. Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹1.06 (vs ₹1.90 in 3Q 2024) Third quarter 2025 results: EPS: ₹1.06 (down from ₹1.90 in 3Q 2024). Revenue: ₹404.1m (down 21% from 3Q 2024). Net income: ₹12.1m (down 44% from 3Q 2024). Profit margin: 3.0% (down from 4.3% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 01
Parnax Lab Limited to Report Q3, 2025 Results on Feb 10, 2025 Parnax Lab Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 10, 2025 Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹178, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 408% over the past three years. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹2.97 (vs ₹1.63 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.97 (up from ₹1.63 in 2Q 2024). Revenue: ₹493.1m (up 16% from 2Q 2024). Net income: ₹34.1m (up 82% from 2Q 2024). Profit margin: 6.9% (up from 4.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹2.07b market cap, or US$24.5m). Announcement • Nov 07
Parnax Lab Limited to Report Q2, 2025 Results on Nov 14, 2024 Parnax Lab Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹180, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 623% over the past three years. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹157, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 40x in the Pharmaceuticals industry in India. Total returns to shareholders of 525% over the past three years. New Risk • Aug 19
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 20% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (₹1.13b market cap, or US$13.5m). Announcement • Aug 16
Parnax Lab Limited, Annual General Meeting, Sep 28, 2024 Parnax Lab Limited, Annual General Meeting, Sep 28, 2024. Reported Earnings • Aug 16
First quarter 2025 earnings released: EPS: ₹3.47 (vs ₹2.90 in 1Q 2024) First quarter 2025 results: EPS: ₹3.47 (up from ₹2.90 in 1Q 2024). Revenue: ₹502.3m (up 3.1% from 1Q 2024). Net income: ₹39.8m (up 20% from 1Q 2024). Profit margin: 7.9% (up from 6.8% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 05
Parnax Lab Limited to Report Q1, 2025 Results on Aug 14, 2024 Parnax Lab Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹109, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 351% over the past three years. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹113, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 310% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹8.38 (vs ₹7.79 in FY 2023) Full year 2024 results: EPS: ₹8.38 (up from ₹7.79 in FY 2023). Revenue: ₹1.90b (up 13% from FY 2023). Net income: ₹96.1m (up 12% from FY 2023). Profit margin: 5.1% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 24
Parnax Lab Limited to Report Q4, 2024 Results on May 30, 2024 Parnax Lab Limited announced that they will report Q4, 2024 results on May 30, 2024 Buy Or Sell Opportunity • May 23
Now 21% undervalued Over the last 90 days, the stock has risen 26% to ₹109. The fair value is estimated to be ₹139, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹151, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 646% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹132, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 551% over the past three years. New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.29b market cap, or US$15.5m). Buy Or Sell Opportunity • Mar 15
Now 23% undervalued Over the last 90 days, the stock has risen 24% to ₹108. The fair value is estimated to be ₹140, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹109, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 382% over the past three years. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹1.90 (vs ₹2.96 in 3Q 2023) Third quarter 2024 results: EPS: ₹1.90 (down from ₹2.96 in 3Q 2023). Revenue: ₹510.9m (up 9.1% from 3Q 2023). Net income: ₹21.8m (down 31% from 3Q 2023). Profit margin: 4.3% (down from 6.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Announcement • Feb 04
Parnax Lab Limited to Report Q3, 2024 Results on Feb 13, 2024 Parnax Lab Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹99.07, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 239% over the past three years. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹1.63 (vs ₹1.83 in 2Q 2023) Second quarter 2024 results: EPS: ₹1.63 (down from ₹1.83 in 2Q 2023). Revenue: ₹428.3m (flat on 2Q 2023). Net income: ₹18.7m (down 11% from 2Q 2023). Profit margin: 4.4% (down from 4.9% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Nov 06
Now 21% undervalued Over the last 90 days, the stock is up 26%. The fair value is estimated to be ₹114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Announcement • Nov 04
Parnax Lab Limited to Report Q2, 2024 Results on Nov 09, 2023 Parnax Lab Limited announced that they will report Q2, 2024 results on Nov 09, 2023 Buying Opportunity • Oct 20
Now 21% undervalued Over the last 90 days, the stock is up 29%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Announcement • Oct 01
Parnax Lab Limited Appoints Harish S. Panpalia as a Non-Executive Independent Director Parnax Lab Limited announced that the Board of Directors of the Company at its meeting held on 29th September, 2023 has Appointed Mr. Harish S. Panpalia (DIN: 10275561) as a Non-Executive Independent Director of the Company, for a consecutive period of Five (5) years, effective 11th August, 2023. Date of Birth: October 24, 1959. Qualification: Masters from Nagpur University, Diploma in Business Management, CAIIB. BS Trainer. Occupation: SERVICE & COPRPORATE ADVISORY. Experience: Seasoned Corporate Banking Professional with more than 39 years of successful career with SBI. Retired in Top Executive Grade in 2019 and since working as Senior Vice President (Debt Syndication) with Pranjal Corporate Services, an Investment Boutique Firm in Mumbai; Specialized in the domain of Corporate Credit, Stress Asset Management, Risk Management, Branch Management; Played a key role in arranging high value credit requirement of various Listed and Large/Medium Corporates; Guided many Corporate Houses for improvisation in Balance sheet and reduction of funding cost, etc; Headed various large size branches of SBI & gained adequate expertise of Administration and resources management; Diligent in Strategy and planning, Deal Evaluation and Structuring; Expertise in handling Restructuring, OTS and Merger and Acquisitions; Good liaison and network in banking sector. Buying Opportunity • Sep 20
Now 21% undervalued Over the last 90 days, the stock is up 48%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹95.55, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 505% over the past three years. Buying Opportunity • Aug 23
Now 21% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: ₹2.90 (vs ₹1.97 in 1Q 2023) First quarter 2024 results: EPS: ₹2.90 (up from ₹1.97 in 1Q 2023). Revenue: ₹489.9m (up 33% from 1Q 2023). Net income: ₹33.2m (up 72% from 1Q 2023). Profit margin: 6.8% (up from 5.3% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth. Announcement • Aug 12
Parnax Lab Limited, Annual General Meeting, Sep 29, 2023 Parnax Lab Limited, Annual General Meeting, Sep 29, 2023. Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹91.94, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 384% over the past three years. Announcement • Aug 04
Parnax Lab Limited to Report Q1, 2024 Results on Aug 11, 2023 Parnax Lab Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹68.36, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 297% over the past three years. Reported Earnings • Jun 04
Full year 2023 earnings released: EPS: ₹7.80 (vs ₹9.68 in FY 2022) Full year 2023 results: EPS: ₹7.80. Revenue: ₹1.68b (up 3.3% from FY 2022). Net income: ₹86.2m (up 4.6% from FY 2022). Profit margin: 5.1% (in line with FY 2022). Announcement • May 23
Parnax Lab Limited to Report Fiscal Year 2023 Results on May 30, 2023 Parnax Lab Limited announced that they will report fiscal year 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₹75.69, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 281% over the past three years. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹2.96 (vs ₹5.37 in 3Q 2022) Third quarter 2023 results: EPS: ₹2.96 (down from ₹5.37 in 3Q 2022). Revenue: ₹468.2m (down 7.6% from 3Q 2022). Net income: ₹31.5m (down 31% from 3Q 2022). Profit margin: 6.7% (down from 9.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 71% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 444% over the past three years. Announcement • Feb 06
Parnax Lab Limited to Report Q3, 2023 Results on Feb 14, 2023 Parnax Lab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023 Announcement • Sep 07
Parnax Lab Limited, Annual General Meeting, Sep 28, 2022 Parnax Lab Limited, Annual General Meeting, Sep 28, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the audited standalone financial statements of the company for the financial year ended 31 march 2022; to consider re-appointment of Mr. Prakash Shah as a director to retire by rotation. Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: ₹1.97 (vs ₹1.15 in 1Q 2022) First quarter 2023 results: EPS: ₹1.97 (up from ₹1.15 in 1Q 2022). Revenue: ₹368.6m (up 28% from 1Q 2022). Net income: ₹19.3m (up 98% from 1Q 2022). Profit margin: 5.2% (up from 3.4% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth. Announcement • Aug 03
Parnax Lab Limited to Report Q1, 2023 Results on Aug 10, 2022 Parnax Lab Limited announced that they will report Q1, 2023 results on Aug 10, 2022 Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 312% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹85.60, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 214% over the past three years. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹105, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 288% over the past three years. Reported Earnings • Jun 02
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹9.70 (up from ₹0.43 loss in FY 2021). Revenue: ₹1.63b (up 81% from FY 2021). Net income: ₹82.4m (up ₹86.1m from FY 2021). Profit margin: 5.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 56% per year. Announcement • May 24
Parnax Lab Limited to Report Q4, 2022 Results on May 30, 2022 Parnax Lab Limited announced that they will report Q4, 2022 results on May 30, 2022 Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 17% share price gain to ₹134, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 356% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improved over the past week After last week's 16% share price gain to ₹135, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improved over the past week After last week's 27% share price gain to ₹102, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years. Reported Earnings • Feb 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: ₹5.37 (up from ₹0.14 in 3Q 2021). Revenue: ₹506.8m (up 104% from 3Q 2021). Net income: ₹45.5m (up ₹44.4m from 3Q 2021). Profit margin: 9.0% (up from 0.5% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 08
Parnax Lab Limited to Report Q3, 2022 Results on Feb 14, 2022 Parnax Lab Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹76.05, the stock trades at a trailing P/E ratio of 75.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 86% over the past three years. Announcement • Jan 03
Parnax Lab Limited announced that it expects to receive INR 45.78375 million in funding Parnax Lab Limited announced a private placement of 4,210,000 pre-paid warrants at an issue price of INR 10.875 for gross proceeds of INR 45,783,750 on January 1, 2022. The transaction will involve participation from individual investors, Prakash Shah, Pragna Prakash Shah, Mihir Prakash Shah, Ami Mihir Prakash Shah for 526,250 warrants each, Baiju Mahashukhlal, Ila Baiju Shah for 701,000 warrants each, and Shah Binoy Baiju for 703,000 warrants. The warrants are convertible into shares at INR 10 each. The transaction has been approved by the board of directors of the company. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 27% share price gain to ₹52.75, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improved over the past week After last week's 17% share price gain to ₹42.25, the stock trades at a trailing P/E ratio of 41.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 10% over the past three years. Reported Earnings • Nov 18
Second quarter 2022 earnings released: EPS ₹3.38 (vs ₹2.82 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹358.2m (up 34% from 2Q 2021). Net income: ₹28.7m (up 20% from 2Q 2021). Profit margin: 8.0% (down from 9.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 16% share price gain to ₹28.95, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improved over the past week After last week's 24% share price gain to ₹31.70, the stock trades at a trailing P/E ratio of 70.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.7% over the past three years. Reported Earnings • Jul 04
Full year 2021 earnings released: ₹0.42 loss per share (vs ₹3.43 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: ₹897.3m (down 6.1% from FY 2020). Net loss: ₹3.62m (loss narrowed 88% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Executive Departure • Jun 08
Company Secretary & Compliance Officer Namrata Kambli has left the company On the 31st of May, Namrata Kambli's tenure as Company Secretary & Compliance Officer ended after 1.5 years in the role. We don't have any record of a personal shareholding under Namrata's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years. Executive Departure • Mar 10
Independent & Non-Executive Director has left the company On the 27th of February, Manharbhai Jhavari's tenure as Independent & Non-Executive Director ended after 9.6 years in the role. We don't have any record of a personal shareholding under Manharbhai's name. Manharbhai is the only executive to leave the company over the last 12 months. Reported Earnings • Feb 15
Third quarter 2021 earnings released: EPS ₹0.14 (vs ₹0.97 loss in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹248.3m (down 2.9% from 3Q 2020). Net income: ₹1.15m (up ₹9.38m from 3Q 2020). Profit margin: 0.5% (up from net loss in 3Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 77% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 09
New 90-day high: ₹37.30 The company is up 103% from its price of ₹18.35 on 11 November 2020. The Indian market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. Announcement • Feb 03
Parnax Lab Limited to Report Q3, 2021 Results on Feb 13, 2021 Parnax Lab Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Is New 90 Day High Low • Jan 25
New 90-day high: ₹31.20 The company is up 68% from its price of ₹18.60 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 09
New 90-day high: ₹30.30 The company is up 72% from its price of ₹17.65 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Nov 13
New 90-day high: ₹21.10 The company is up 11% from its price of ₹19.00 on 14 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Reported Earnings • Sep 19
First quarter earnings released Over the last 12 months the company has reported total losses of ₹27.6m, with earnings decreasing by ₹53.7m from the prior year. Total revenue was ₹923.0m over the last 12 months, down 15% from the prior year. Announcement • Sep 05
Parnax Lab Limited to Report Q1, 2021 Results on Sep 15, 2020 Parnax Lab Limited announced that they will report Q1, 2021 results on Sep 15, 2020 Announcement • Jun 21
Parnax Lab Limited to Report Q4, 2020 Results on Jun 30, 2020 Parnax Lab Limited announced that they will report Q4, 2020 results on Jun 30, 2020 